25 LLC’s Bristol-Myers Squibb BMY Stock Holding History

25 LLC’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14	Closed	-$958	–	629
2023 Q1	$958	Buy	+14	New	+$987	﹤0.01%	238

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

25 LLC's BMY Position: Q2 2023 in Review

25 LLC sold out of Bristol-Myers Squibb (BMY) in Q2 2023, closing a stake of 14 shares — an estimated $958 sold.

25 LLC first reported a position in BMY in Q1 2023 and held it in 1 quarter. The position peaked at $958 in Q1 2023. 2,480 funds tracked by Wall St. Rank hold BMY as of Q2 2023.

25 LLC reported no remaining Bristol-Myers Squibb position as of Q2 2023 after selling out during the quarter.
25 LLC sold 14 Bristol-Myers Squibb shares in Q2 2023, an estimated $958.
25 LLC first reported a position in Bristol-Myers Squibb in Q1 2023 and held it in 1 quarter.
25 LLC's Bristol-Myers Squibb position peaked at $958 in Q1 2023.
2,480 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.

Based on 25 LLC's 13F filing for Q2 2023, filed 19 Jul 2023.